New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 7, Pages 647-669
Publisher
Springer Science and Business Media LLC
Online
2020-04-18
DOI
10.1007/s40265-020-01304-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- HALO 109-301: A randomized, double-blind, placebo-controlled, phase 3 study of pegvorhyaluronidase alfa (PEGPH20) + nab-paclitaxel/gemcitabine (AG) in patients (pts) with previously untreated hyaluronan (HA)-high metastatic pancreatic ductal adenocarcinoma (mPDA).
- (2020) Margaret A. Tempero et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
- (2019) Alok A. Khorana et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers
- (2019) Conan G. Kinsey et al. NATURE MEDICINE
- Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
- (2019) Kirsten L. Bryant et al. NATURE MEDICINE
- Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
- (2019) Ramesh K. Ramanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Dosing modifications to increase tolerability of gemcitabine and nab-paclitaxel in treatment of pancreatic cancer in the elderly.
- (2019) Jasmine L Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review
- (2019) Ritu R. Singh et al. CANCER TREATMENT REVIEWS
- A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study)
- (2019) Dung T. Le et al. CLINICAL CANCER RESEARCH
- NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma
- (2019) Martin R Jones et al. CLINICAL CANCER RESEARCH
- Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.
- (2019) Saroj Vadhan-Raj et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.
- (2019) Marwan Fakih et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
- (2019) Thomas B. Karasic et al. JAMA Oncology
- Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
- (2019) Sara Pusceddu et al. Cancers
- O-002Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
- (2019) M Tempero et al. ANNALS OF ONCOLOGY
- SO-005A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
- (2019) Z Wainberg et al. ANNALS OF ONCOLOGY
- P-304Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with performance status two or less
- (2019) A Das et al. ANNALS OF ONCOLOGY
- P-065A multicenter retrospective study of gemcitabine plus nab-paclitaxel or FOLFIRINOX in metastatic pancreatic cancer: NAPOLEON study
- (2019) J Nakazawa et al. ANNALS OF ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
- (2019) Emilie Charton et al. Cancer Medicine
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
- (2019) Nigel S. Key et al. JOURNAL OF CLINICAL ONCOLOGY
- Early-onset pancreatic cancer: a population-based study using the SEER registry
- (2019) Daniel Ansari et al. LANGENBECKS ARCHIVES OF SURGERY
- Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
- (2019) Roberto Petrioli et al. Journal of Geriatric Oncology
- Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
- (2019) E M O’Reilly et al. ANNALS OF ONCOLOGY
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
- (2019) Christopher Nevala-Plagemann et al. Nature Reviews Clinical Oncology
- Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study
- (2019) Suneel D. Kamath et al. ONCOLOGIST
- The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
- (2019) Jill Hallin et al. Cancer Discovery
- Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer
- (2019) Gayle S. Jameson et al. JAMA Oncology
- Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
- (2019) Max M. Wattenberg et al. BRITISH JOURNAL OF CANCER
- Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial
- (2019) Pascal Hammel et al. EUROPEAN JOURNAL OF CANCER
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distinct Pathogenesis of Pancreatic Cancer Microvesicle–Associated Venous Thrombosis Identifies New Antithrombotic Targets In VivoHighlights
- (2018) Konstantin Stark et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/− nab-paclitaxel in elderly pancreatic cancer patients (GrantPax)
- (2018) Johannes Betge et al. BMC CANCER
- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma
- (2018) Eileen M. O'Reilly et al. CANCER
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Integrated genomic and immunophenotypic classification of pancreatic cancer reveals three distinct subtypes with prognostic/predictive significance
- (2018) Martin Wartenberg et al. CLINICAL CANCER RESEARCH
- Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative
- (2018) Michael J. Pishvaian et al. CLINICAL CANCER RESEARCH
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma
- (2018) Maeve A. Lowery et al. EUROPEAN JOURNAL OF CANCER
- Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
- (2018) Renato M. Lupinacci et al. GASTROENTEROLOGY
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
- (2018) Sunil R. Hingorani et al. JOURNAL OF CLINICAL ONCOLOGY
- Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update
- (2018) Davendra P.S. Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
- (2018) William H. Isacoff et al. Targeted Oncology
- Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine
- (2018) Andrew J Aguirre et al. Cancer Discovery
- NRG1 Fusions in KRAS Wild-type Pancreatic Cancer
- (2018) Christoph Heining et al. Cancer Discovery
- Demographic, clinical, and pathological features of early onset pancreatic cancer patients
- (2018) Chara Ntala et al. BMC GASTROENTEROLOGY
- Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients.
- (2018) Vincent J. Picozzi et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
- (2018) Laetitia Dahan et al. JOURNAL OF CLINICAL ONCOLOGY
- 790TiPA phase II clinical investigation of BPM31510-IV (ubidecarenone) in patients with advanced pancreatic cancer
- (2018) A A Niewiarowska et al. ANNALS OF ONCOLOGY
- Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives
- (2018) Marina Macchini et al. CANCER TREATMENT REVIEWS
- Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer
- (2018) Amit Mahipal et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2
- (2018) Teresa Macarulla et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
- (2018) Alicia Latham et al. JOURNAL OF CLINICAL ONCOLOGY
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypermutation In Pancreatic Cancer
- (2017) Jeremy L. Humphris et al. GASTROENTEROLOGY
- Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
- (2017) Glen J. Weiss et al. INVESTIGATIONAL NEW DRUGS
- Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience.
- (2017) Courtney C Cavalieri et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BRCAness on the efficacy of oxaliplatin-based chemotherapy in patients with unresectable pancreatic cancer.
- (2017) Tomohiro Kondo et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Targetable ALK Rearrangements in Pancreatic Ductal Adenocarcinoma
- (2017) Aatur D. Singhi et al. Journal of the National Comprehensive Cancer Network
- Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
- (2017) Angela Alistar et al. LANCET ONCOLOGY
- Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells
- (2017) Kayleigh C. Ross et al. MOLECULAR CANCER THERAPEUTICS
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy
- (2017) Vincent Chung et al. JAMA Oncology
- Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers
- (2017) Diána Brauswetter et al. PLoS One
- Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
- (2016) Scott A. Foster et al. CANCER CELL
- Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
- (2016) E Eriksson et al. GENE THERAPY
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review
- (2016) Lei Zhou et al. MEDICAL ONCOLOGY
- Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
- (2016) P. Lito et al. SCIENCE
- Subtyping Pancreatic Cancer
- (2015) Andrew V. Biankin et al. CANCER CELL
- Abstract CT315: Phase I study of BPM 31510 (ubidecarenone) in patients with advanced solid tumors
- (2015) Manish A. Shah et al. CANCER RESEARCH
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma
- (2015) Daneng Li et al. Clinical Colorectal Cancer
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- The Path to Cancer — Three Strikes and You're Out
- (2015) Bert Vogelstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma
- (2015) Jean-Baptiste Bachet et al. PANCREAS
- Early onset pancreatic cancer: Risk factors, presentation and outcome
- (2015) Matteo Piciucchi et al. PANCREATOLOGY
- RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
- (2015) Talia Golan et al. Oncotarget
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Stromal reengineering to treat pancreas cancer
- (2014) I. M. Stromnes et al. CARCINOGENESIS
- Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy
- (2014) Mara H. Sherman et al. CELL
- Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity
- (2014) Ingunn M Stromnes et al. GUT
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma
- (2014) B. M. Wolpin et al. ONCOLOGIST
- A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
- (2013) A H Ko et al. BRITISH JOURNAL OF CANCER
- Inflammatory networks and immune surveillance of pancreatic carcinoma
- (2013) Robert H Vonderheide et al. CURRENT OPINION IN IMMUNOLOGY
- Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
- (2013) Dung T. Le et al. JOURNAL OF IMMUNOTHERAPY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
- (2012) S Boeck et al. BRITISH JOURNAL OF CANCER
- Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors
- (2012) S. Yachida et al. CLINICAL CANCER RESEARCH
- Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients
- (2012) J. THALER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer
- (2011) Andrew S. Epstein et al. CANCER
- Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo
- (2011) Zuzana Zachar et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer
- (2011) Laurel A. Menapace et al. THROMBOSIS AND HAEMOSTASIS
- Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis
- (2011) Ibrahim T. Aldoss et al. Journal of Geriatric Oncology
- ATM Mutations in Patients with Hereditary Pancreatic Cancer
- (2011) Nicholas J. Roberts et al. Cancer Discovery
- 19-nor-1α,25-Dihydroxyvitamin D2(Paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo
- (2010) Gary G. Schwartz et al. CANCER BIOLOGY & THERAPY
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Distant metastasis occurs late during the genetic evolution of pancreatic cancer
- (2010) Shinichi Yachida et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now